Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography–tandem mass spectrometry-Reference-Cited by-同舟云学术

Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography–tandem mass spectrometry

Published:2022-08-31 Issue:11 Volume:36 Page:
ISSN:0269-3879
Container-title:Biomedical Chromatography
language:en
Short-container-title:Biomedical Chromatography

Author:

Kagan Amanda B.¹^ORCID,Anders Nicole M.²³,Hemingway Avelina²³,Lee Eudocia Q.⁴,Kelly Kevin R.⁵,Lee Hans C.⁶^ORCID,Xu‐Welliver Meng⁷,Piekarz Richard⁸^ORCID,Rudek Michelle A.¹²³^ORCID

Affiliation:

1. Division of Clinical Pharmacology, Department of Medicine, School of Medicine Johns Hopkins University Baltimore MD USA

2. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Baltimore MD USA

3. Department of Oncology, School of Medicine Johns Hopkins University Baltimore MD USA

4. Dana‐Farber Cancer Institute Boston MA USA

5. Division of Hematology Keck School of Medicine of the University of Southern California Los Angeles CA USA

6. Department of Lymphoma/Myeloma, Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston TX USA

7. Department of Radiation Oncology The Ohio State University Columbus OH USA

8. Investigational Drug Branch, Cancer Therapy Evaluation Program (CTEP) National Cancer Institute Bethesda MD USA

Funder

National Cancer Institute

National Center for Advancing Translational Sciences

National Institutes of Health

Publisher

Wiley

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,General Medicine,Biochemistry,Analytical Chemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bmc.5467

Reference13 articles.

1. The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents

2. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia

3. Food and Drug Administration Center for Drug Evaluation and Research U.S. Department of Health and Human Services. (2018).Guidance for industry bioanalytical method validation. Retrieved from

4. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

5. The first 30 years of p53: growing ever more complex

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma;2024-08-14